Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Veracyte, Inc. or Aurinia Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Veracyte, Inc. and Aurinia Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Veracyte, Inc. and Aurinia Pharmaceuticals Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Latest Biotechnology and Veracyte, Inc., Aurinia Pharmaceuticals Inc. Stock News

As of May 15, 2026, Veracyte, Inc. had a $3.1 billion market capitalization, compared to the Biotechnology median of $275.0 million. Veracyte, Inc.’s stock is down 8.6% in 2026, down 4.8% in the previous five trading days and up 35.07% in the past year.

Currently, Veracyte, Inc.’s price-earnings ratio is 35.6. Veracyte, Inc.’s trailing 12-month revenue is $541.7 million with a 16.2% net profit margin. Year-over-year quarterly sales growth most recently was 21.5%. Analysts expect adjusted earnings to reach $1.824 per share for the current fiscal year. Veracyte, Inc. does not currently pay a dividend.

As of May 15, 2026, Aurinia Pharmaceuticals Inc. had a $2.0 billion market cap, putting it in the 54th percentile of all stocks. Aurinia Pharmaceuticals Inc.’s stock is down 4.2% in 2026, up 0.3% in the previous five trading days and up 94.65% in the past year.

Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 7.0. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $298.3 million with a 100.0% net profit margin. Year-over-year quarterly sales growth most recently was 24.3%. Analysts expect adjusted earnings to reach $0.960 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.

How We Compare Veracyte, Inc. and Aurinia Pharmaceuticals Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Veracyte, Inc. and Aurinia Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Veracyte, Inc. and Aurinia Pharmaceuticals Inc. Stock Value Grades

Company	Ticker	Value
Veracyte, Inc.	VCYT	F
Aurinia Pharmaceuticals Inc.	AUPH	B

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Veracyte, Inc. has a Value Score of 20, which is Ultra Expensive. Aurinia Pharmaceuticals Inc. has a Value Score of 65, which is Value.

The Value Stock Winner: Aurinia Pharmaceuticals Inc.

As you can clearly see from the Value Grade breakdown above, Aurinia Pharmaceuticals Inc. is considered to have better value than Veracyte, Inc.. For investors who focus solely on a company’s valuation, Aurinia Pharmaceuticals Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Veracyte, Inc. and Aurinia Pharmaceuticals Inc. Growth Grades

Company	Ticker	Growth
Veracyte, Inc.	VCYT	D
Aurinia Pharmaceuticals Inc.	AUPH	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Veracyte, Inc. has a Growth Score of 40, which is Weak. Aurinia Pharmaceuticals Inc. has a Growth Score of 26, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Veracyte, Inc. or Aurinia Pharmaceuticals Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Veracyte, Inc. or Aurinia Pharmaceuticals Inc. is the better investment when it comes to sustainable growth.

Veracyte, Inc. and Aurinia Pharmaceuticals Inc.’s Momentum Grades

Company	Ticker	Momentum
Veracyte, Inc.	VCYT	B
Aurinia Pharmaceuticals Inc.	AUPH	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Veracyte, Inc. has a Momentum Score of 68, which is Strong. Aurinia Pharmaceuticals Inc. has a Momentum Score of 81, which is Very Strong.

The Momentum Grade Winner: Aurinia Pharmaceuticals Inc.

As you can clearly see from the Momentum Grade breakdown above, Aurinia Pharmaceuticals Inc. is considered to have stronger momentum compared to Veracyte, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Aurinia Pharmaceuticals Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Veracyte, Inc. and Aurinia Pharmaceuticals Inc. Grades

In addition to Value, Growth and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Veracyte, Inc. and Aurinia Pharmaceuticals Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Veracyte, Inc. or Aurinia Pharmaceuticals Inc. Stock?

Overall, Veracyte, Inc. stock has a Value Score of 20, Growth Score of 40 and Momentum Score of 68.

Aurinia Pharmaceuticals Inc. stock has a Value Score of 65, Growth Score of 26 and Momentum Score of 81.

Comparing Veracyte, Inc. and Aurinia Pharmaceuticals Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.